Pfizer Inc. (PFE) Q3 2026 (USD): Adj. EPS 0.87 (exp. 0.73), Revenue 16.6bln (exp. 15.85bln), Current FY EPS 2.95-3.05 (exp. 2.96), Current FY Rev. 62-64bln (exp. 62.24bln)

Paxlovid globally, down USD 771mln, or 63%, operationally, driven primarily by lower COVID-19 infections across the U.S. and international markets, partially offset by timing of government purchases in certain emerging markets. Third-quarter 2026 R&D Expenses increased 18% operationally compared to the prior-year quarter, driven primarily by an anticipated net increase in spending in certain oncology and obesity product candidates, as well as an increase in compensation-related expenses in the quarter. No share repurchases have been completed to date in 2026. As of November 3, 2026, Pfizer’s remaining share repurchase authorization is USD 3.3bln. Will advance 10 ongoing or planned Phase III clinical trials in 2026.